Facing an uncertain market environment, investors ought to consider the top healthcare stocks that pay dividends. Sure, the Federal Reserve may be in a position to facilitate a soft landing for the...

AbbVie, McDonald's, and Comcast all provide investors with above-average yields. They have been increasing their payouts for years, and more increases are likely on the way.

The lengthy negotiation process with Medicare won't end until August 2024, with reduced prices going into effect in January 2026.

All the drugmakers that make the 10 prescription medicines subject to the first-ever price negotiations for the U.S. Medicare health program, including Amgen and Novartis , said they signed on to p...

UnitedHealth is showing no signs of slowing down. Pfizer's sell-off has gone too far.

Fifteen long-term dividend growth companies, AbbVie among them, will announce their annual increases in October. Most of the increases will be in the single digit range, with 10%+ increases expecte...

Clinical trials are a difficult and grueling process for companies. The FDA and other regulatory agencies require the highest possible standards in order to approve new drugs.

AbbVie said on Friday a late-stage study of its experimental combination therapy failed to show meaningful increase in the survival of patients with a form of blood cancer without the disease worse...

Diamondback's variable dividend offers even more upside potential from this red-hot oil stock. NextEra Energy Partners generates steady cash flows from its sizable renewable energy portfolio.

In the dynamic investment realm, one sector that continues to stand out is the area of biotech stocks. Though risky, especially when assessing established firms with market-ready drugs and vast res...

AbbVie ABBV and partner Genmab GMAB announced that the European Commission has granted conditional marketing authorization to epcoritamab for treating relapsed or refractory (R/R) diffuse large B-c...

China-based biotech company I-Mab said on Friday that AbbVie has terminated a 2020 deal to co-develop and market I-Mab's lead cancer drug candidate lemzoparlimab.

AbbVie is entering a new era but is well prepared to return to its winning ways. Gilead Sciences offers investors steady and reliable performance and a great dividend.

If you're looking for a sector that's on sale, look to healthcare. The Health Care Select Sector SPDR Fund NYSEARCA: XLV is down 2.50% in the past month, lagging the S&P 500.

Navigating the unpredictable waters of today's market, safe dividend stocks emerge as a beacon of reliability. Despite an optimistic kickoff this year, the broader market sentiment has chilled.